Publications. multiple sclerosis, Value in Health Simone Huygens 12/15/21 multiple sclerosis, Value in Health Simone Huygens 12/15/21 Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple Sclerosis Read More quality of life, Value in Health Matthijs Versteegh 10/25/21 quality of life, Value in Health Matthijs Versteegh 10/25/21 Performance of the EQ-5D-5L Plus Respiratory Bolt-On in the Birmingham Chronic Obstructive Pulmonary Disease Cohort Study Read More multiple sclerosis, Brain Sciences, artificial intelligence Matthijs Versteegh 9/30/21 multiple sclerosis, Brain Sciences, artificial intelligence Matthijs Versteegh 9/30/21 The potential impact of digial biomarkers in multiple slerosis in the Netherlands: an early HTA technology assessment of MS Sherpa Read More personalised medicine, Annals of Oncology Matthijs Versteegh 9/1/21 personalised medicine, Annals of Oncology Matthijs Versteegh 9/1/21 105P prognostic value of the NTRK fusion biomarker in the Netherlands Read More multiple sclerosis, Value in Health Simone Huygens 8/10/21 multiple sclerosis, Value in Health Simone Huygens 8/10/21 Modeling the Cost-Utility of Treatment Sequences for Multiple Sclerosis Read More methods, Health Economics Matthijs Versteegh 7/30/21 methods, Health Economics Matthijs Versteegh 7/30/21 Distributional consequences of including survivor costs in economic evaluations distributional consequences of survivor costs in economic evaluations Read More quality of life, The Lancet: Regional Health Europe Matthijs Versteegh 7/19/21 quality of life, The Lancet: Regional Health Europe Matthijs Versteegh 7/19/21 Quality of life among people living with HIV in England and the Netherlands: a population-based study Read More quality of life, Quality of Life Research Matthijs Versteegh 7/9/21 quality of life, Quality of Life Research Matthijs Versteegh 7/9/21 The Mental Health Quality of Life Questionnaire (MHQoL): development and first psychometric evaluation of a new measure to assess quality of life in people with mental health problems Read More epilepsy, quality of life, Value in Health Matthijs Versteegh 7/2/21 epilepsy, quality of life, Value in Health Matthijs Versteegh 7/2/21 Good Days and Bad Days: Measuring Health-Related Quality of Life in People With Epilepsy Read More methods, personalised medicine, Pharmacoeconomics Matthijs Versteegh 4/16/21 methods, personalised medicine, Pharmacoeconomics Matthijs Versteegh 4/16/21 Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine Read More methods, rare diseases, Pharmacoeconomics Matthijs Versteegh 2/19/21 methods, rare diseases, Pharmacoeconomics Matthijs Versteegh 2/19/21 Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision Read More heart failure, informal care, Value in Health Matthijs Versteegh 2/2/21 heart failure, informal care, Value in Health Matthijs Versteegh 2/2/21 Burden of providing informal care for patients with atrial fibrillation Read More heart failure, Netherlands Heart Journal Matthijs Versteegh 11/27/20 heart failure, Netherlands Heart Journal Matthijs Versteegh 11/27/20 A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure Read More NICE STA, rare diseases Matthijs Versteegh 11/16/20 NICE STA, rare diseases Matthijs Versteegh 11/16/20 Ravulizumab for paroxysmal nocturnal haemoglobinuria: a Single Technology Assessment Read More methods, NTvG Matthijs Versteegh 8/18/20 methods, NTvG Matthijs Versteegh 8/18/20 Pharmaceutical pricing: what is reasonable? Read More quality of life, Health & Quality of Life Outcomes Matthijs Versteegh 7/20/20 quality of life, Health & Quality of Life Outcomes Matthijs Versteegh 7/20/20 Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model Read More cardiac disease, European Journal of Health Economics Simone Huygens 6/17/20 cardiac disease, European Journal of Health Economics Simone Huygens 6/17/20 Early cost-utility analysis of tissue-engineered heart valves compared to bioprostheses in the aortic position in elderly patients Read More multiple sclerosis, Medical Decision Making Matthijs Versteegh 2/17/20 multiple sclerosis, Medical Decision Making Matthijs Versteegh 2/17/20 Summarizing patient preferences for the competitive landscape of multiple sclerosis treatment options Read More epilepsy, trial protocol, Frontiers in Neurology Matthijs Versteegh 1/22/20 epilepsy, trial protocol, Frontiers in Neurology Matthijs Versteegh 1/22/20 Evaluating the Effectiveness and Cost-Effectiveness of Seizure Dogs in Persons With Medically Refractory Epilepsy in the Netherlands Read More trial protocol, BMJ Open Matthijs Versteegh 1/19/20 trial protocol, BMJ Open Matthijs Versteegh 1/19/20 Protocol: comparing the effectiveness and cost-effectiveness of self-management interventions in four high-priority chronic conditions in Europe (COMPAR-EU): a research protocol Read More Newer Posts Older Posts
multiple sclerosis, Value in Health Simone Huygens 12/15/21 multiple sclerosis, Value in Health Simone Huygens 12/15/21 Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple Sclerosis Read More
quality of life, Value in Health Matthijs Versteegh 10/25/21 quality of life, Value in Health Matthijs Versteegh 10/25/21 Performance of the EQ-5D-5L Plus Respiratory Bolt-On in the Birmingham Chronic Obstructive Pulmonary Disease Cohort Study Read More
multiple sclerosis, Brain Sciences, artificial intelligence Matthijs Versteegh 9/30/21 multiple sclerosis, Brain Sciences, artificial intelligence Matthijs Versteegh 9/30/21 The potential impact of digial biomarkers in multiple slerosis in the Netherlands: an early HTA technology assessment of MS Sherpa Read More
personalised medicine, Annals of Oncology Matthijs Versteegh 9/1/21 personalised medicine, Annals of Oncology Matthijs Versteegh 9/1/21 105P prognostic value of the NTRK fusion biomarker in the Netherlands Read More
multiple sclerosis, Value in Health Simone Huygens 8/10/21 multiple sclerosis, Value in Health Simone Huygens 8/10/21 Modeling the Cost-Utility of Treatment Sequences for Multiple Sclerosis Read More
methods, Health Economics Matthijs Versteegh 7/30/21 methods, Health Economics Matthijs Versteegh 7/30/21 Distributional consequences of including survivor costs in economic evaluations distributional consequences of survivor costs in economic evaluations Read More
quality of life, The Lancet: Regional Health Europe Matthijs Versteegh 7/19/21 quality of life, The Lancet: Regional Health Europe Matthijs Versteegh 7/19/21 Quality of life among people living with HIV in England and the Netherlands: a population-based study Read More
quality of life, Quality of Life Research Matthijs Versteegh 7/9/21 quality of life, Quality of Life Research Matthijs Versteegh 7/9/21 The Mental Health Quality of Life Questionnaire (MHQoL): development and first psychometric evaluation of a new measure to assess quality of life in people with mental health problems Read More
epilepsy, quality of life, Value in Health Matthijs Versteegh 7/2/21 epilepsy, quality of life, Value in Health Matthijs Versteegh 7/2/21 Good Days and Bad Days: Measuring Health-Related Quality of Life in People With Epilepsy Read More
methods, personalised medicine, Pharmacoeconomics Matthijs Versteegh 4/16/21 methods, personalised medicine, Pharmacoeconomics Matthijs Versteegh 4/16/21 Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine Read More
methods, rare diseases, Pharmacoeconomics Matthijs Versteegh 2/19/21 methods, rare diseases, Pharmacoeconomics Matthijs Versteegh 2/19/21 Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision Read More
heart failure, informal care, Value in Health Matthijs Versteegh 2/2/21 heart failure, informal care, Value in Health Matthijs Versteegh 2/2/21 Burden of providing informal care for patients with atrial fibrillation Read More
heart failure, Netherlands Heart Journal Matthijs Versteegh 11/27/20 heart failure, Netherlands Heart Journal Matthijs Versteegh 11/27/20 A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure Read More
NICE STA, rare diseases Matthijs Versteegh 11/16/20 NICE STA, rare diseases Matthijs Versteegh 11/16/20 Ravulizumab for paroxysmal nocturnal haemoglobinuria: a Single Technology Assessment Read More
methods, NTvG Matthijs Versteegh 8/18/20 methods, NTvG Matthijs Versteegh 8/18/20 Pharmaceutical pricing: what is reasonable? Read More
quality of life, Health & Quality of Life Outcomes Matthijs Versteegh 7/20/20 quality of life, Health & Quality of Life Outcomes Matthijs Versteegh 7/20/20 Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model Read More
cardiac disease, European Journal of Health Economics Simone Huygens 6/17/20 cardiac disease, European Journal of Health Economics Simone Huygens 6/17/20 Early cost-utility analysis of tissue-engineered heart valves compared to bioprostheses in the aortic position in elderly patients Read More
multiple sclerosis, Medical Decision Making Matthijs Versteegh 2/17/20 multiple sclerosis, Medical Decision Making Matthijs Versteegh 2/17/20 Summarizing patient preferences for the competitive landscape of multiple sclerosis treatment options Read More
epilepsy, trial protocol, Frontiers in Neurology Matthijs Versteegh 1/22/20 epilepsy, trial protocol, Frontiers in Neurology Matthijs Versteegh 1/22/20 Evaluating the Effectiveness and Cost-Effectiveness of Seizure Dogs in Persons With Medically Refractory Epilepsy in the Netherlands Read More
trial protocol, BMJ Open Matthijs Versteegh 1/19/20 trial protocol, BMJ Open Matthijs Versteegh 1/19/20 Protocol: comparing the effectiveness and cost-effectiveness of self-management interventions in four high-priority chronic conditions in Europe (COMPAR-EU): a research protocol Read More